摘要

Objectives: To assess the efficacy and safety of the treatment of AGA and menopausal hair thinning with autologous exosomes injected on the scalp. Introduction: Androgenetic alopecia (AGA) is the most prevalent cause of hair loss in males and females. It is a genetically predetermined disorder due to an excessive response to androgens. Menopausal hair thinning is also common, driven by declining estrogen and progesterone, which allows androgens to shrink hair follicles, leading to slower growth, finer strands, and increased shedding, often seen as a widening part or reduced global volume of hair. Materials / method: This is a retrospective case series. We reviewed patients records from a private dermatology and trichology clinic that were diagnosed with AGA or menopausal hair thinning and received treatment with autologous exosomes injected on the scalp. The autologous exosomes were obtained through medical device, which is a closed, sterile, single use Class II FDA cleared medical device designed to process plasma and prepare a secretome rich autologous platelet concentrate (APC). Results: Patients were evaluated through standard pictures and/or Digital Trichoscopy (Hairmetrix). The majority of patients (more than 50%) exhibited an improvement in hair density and hair regrowth according to the standard pictures. The statistical analysis is still in process. Patient satisfaction was generally high (3–10 point scales). No serious adverse events were noted, only temporary small discomfort during injection and temporary local pruritus. Conclusion: However, a considerable number of patients were also receiving another concomitant hair therapy. This bias should be considered and future studies with monotherapy should be done to evaluate the efficacy of autologous exosomes in the treatment of AGA and Menopausal hair thinning.